Article
Oncology
Jin Zhang, Hongchuan Jiang, Jian Zhang, Guoqiang Bao, Guoqiang Zhang, Haibo Wang, Xi Wang
Summary: In neoadjuvant and adjuvant treatment of breast cancer, Pegylated liposomal doxorubicin (PLD) showed similar effectiveness but different toxicities compared to epirubicin. PLD was found to be non-inferior to epirubicin in adjuvant chemotherapy for breast cancer, with lower rates of certain adverse reactions. Further studies are needed to explore the use of PLD-based chemotherapy for breast cancer.
Article
Medicine, General & Internal
Peng Yuan, Yikun Kang, Fei Ma, Ying Fan, Jiayu Wang, Xue Wang, Jian Yue, Yang Luo, Pin Zhang, Qing Li, Binghe Xu
Summary: This study aimed to compare the efficacy of the cyclophosphamide-free epirubicin plus paclitaxel (EP) regimen with the standard epirubicin and cyclophosphamide followed by paclitaxel (EC-P) regimen in operable hormone receptor-positive, ERBB2-negative, lymph node-positive breast cancer patients. The study found that the EP regimen was noninferior to the EC-P regimen, supporting its effectiveness as an adjuvant chemotherapy regimen for women with ERBB2-negative breast cancer.
Article
Medicine, General & Internal
Peng Yuan, Yikun Kang, Fei Ma, Ying Fan, Jiayu Wang, Xue Wang, Jian Yue, Yang Luo, Pin Zhang, Qing Li, Binghe Xu
Summary: This study compared the efficacy of two different chemotherapy regimens for breast cancer and found that the EP regimen is noninferior to the standard EC-P regimen in terms of disease-free survival and overall survival. However, the EP regimen may lead to more frequent toxic effects.
Article
Multidisciplinary Sciences
Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah, Taher Al-Tweigeri
Summary: The combination therapy of Durvalumab and Paclitaxel is safe and effective in metastatic TNBC, with common adverse events including headache, peripheral neuropathy, fatigue, and skin rash. The confirmed objective response rate was observed in five patients, with a median duration of 10.0 months, and the median progression-free survival and overall survival were 5 and 20.7 months, respectively.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Andreas Schneeweiss, Laura L. Michel, Volker Moebus, Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl-Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch, Jens-Uwe Blohmer, Peter A. Fasching, Christine Solbach, Rita K. Schmutzler, Jens Huober, Kerstin Rhiem, Valentina Nekljudova, Kristina Luebbe, Sibylle Loibl
Summary: GeparOcto demonstrated that intense dose-dense chemotherapy with iddEPC is comparable to weekly chemotherapy with PM(Cb) in achieving pathological complete response (pCR) in high-risk early breast cancer, specifically triple negative breast cancer (TNBC). The study found no significant difference in overall survival (OS) and invasive disease-free survival (iDFS) between the two treatment regimens for the entire cohort. However, HR+/HER2+ patients benefited significantly in terms of iDFS and OS from iddEPC.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Hannah C. Timmins, Tiffany Li, Terry Trinh, Matthew C. Kiernan, Michelle Harrison, Frances Boyle, Michael Friedlander, David Goldstein, Susanna B. Park
Summary: The study reveals that weekly paclitaxel treatment can induce neuropathy early on and patients may require closer monitoring. Dose reduction does not necessarily result in better neuropathy outcomes, with individual risk factors also playing a significant role.
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Huijing Tan, Lijie Zuo, Shutao Ma, Dingyuan Wang, Rui Li, Yiqi Yang, Weili Liu, Yihebali Chi
Summary: This retrospective study evaluated the efficacy and safety of epirubicin combined with temozolomide (EPI-TMZ) for advanced LMS. Results showed a median PFS of 10 months, an ORR of 53.3%, and a DCR of 100.0%. Common adverse effects included leukopenia, neutropenia, and nausea, with no treatment-related deaths recorded.
CANCER MANAGEMENT AND RESEARCH
(2021)
Review
Medicine, General & Internal
Natalie Y. L. Ngoi, Nicholas L. X. Syn, Robby M. Goh, Boon Cher Goh, Ruby Yun-Ju Huang, Yu Yang Soon, Elizabeth James, Adrian Cook, Andrew Clamp, David S. P. Tan
Summary: This study compared the efficacy and tolerability of weekly paclitaxel and tri-weekly paclitaxel, both in combination with carboplatin, as first-line treatment for epithelial ovarian cancer. The results showed that weekly paclitaxel may slightly improve progression-free survival (PFS), but does not affect overall survival (OS). Additionally, weekly paclitaxel is associated with an increased risk of high-grade anemia.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Oncology
Wenyu Zhu, Qian Geng, Haoliang Peng, Zhihui Jin, Dongqing Li, Xiaolin Pu, Ge Wang, Hua Jiang
Summary: The combination of low-dose nanoparticle albumin-bound paclitaxel and tislelizumab shows promising efficacy and safety in elderly patients with advanced non-small cell lung cancer, including those with EGFR/ALK variations.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Yunlong Chen, Jiangning Gu, Menghong Yin, Chenqi Wang, Dan Chen, Lili Yang, Xiang Chen, Zhikun Lin, Jian Du, Shimeng Cui, Chi Ma, Haifeng Luo
Summary: In comparing S1 monotherapy with combination therapy of nab-paclitaxel, the latter showed higher objective response rate and disease control rate in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma. Although the combination therapy had a higher risk of leukopenia, there were no significant differences in other side effects like thrombocytopenia, neurotoxicity, vomiting, and alopecia. Hence, the combination of nab-paclitaxel and S1 appears to be a safe and effective option for elderly patients.
Article
Oncology
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Summary: This study evaluated the efficacy and safety of nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide as neoadjuvant therapy in patients with triple-negative breast cancer, showing promising anti-tumor activity and acceptable tolerability.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Obstetrics & Gynecology
Roy Kessous, Emad Matanes, Ido Laskov, Tamar Wainstock, Jeremie Abitbol, Amber Yasmeen, Shannon Salvador, Susie Lau, Walter H. Gotlieb
Summary: The study showed that patients with advanced ovarian cancer who received dose-dense weekly paclitaxel had significantly better progression-free survival compared to those who received standard 3-weekly chemotherapy. Although the overall survival was also better in the dose-dense group, the difference was not statistically significant. The dose-dense protocol was associated with higher rates of side effects but may be considered as a treatment alternative for advanced ovarian cancer patients.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
(2021)
Article
Oncology
Xin Chen, Junhao Tu, Xiaolan Xu, Wen Gu, Lei Qin, Haixin Qian, Zhenyu Jia, Chuntao Ma, Yinkai Xu
Summary: This study found that adjuvant chemotherapy in elderly patients with stage III colon cancer can reduce cancer-specific mortality rate, but the benefit of chemotherapy in stage II colon cancer patients is suboptimal.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Marc Ychou, Michel Rivoire, Simon Thezenas, Rosine Guimbaud, Francois Ghiringhelli, Anne Mercier-Blas, Laurent Mineur, Eric Francois, Faiza Khemissa, Marion Chauvenet, Reza Kianmanesh, Marianne Fonck, Philippe Houyau, Thomas Aparicio, Marie-Pierre Galais, Franck Audemar, Eric Assenat, Evelyne Lopez-Crapez, Claire Jouffroy, Antoine Adenis, Rene Adam, Olivier Bouche
Summary: The study found that in CRC patients initially deemed unresectable, there was no significant increase in R0/R1 liver-resection rate by using 3-CTx combined with bevacizumab or cetuximab based on RAS status.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Emeric Limagne, Lisa Nuttin, Marion Thibaudin, Elise Jacquin, Romain Aucagne, Marjorie Bon, Solene Revy, Robby Barnestein, Elise Ballot, Caroline Truntzer, Valentin Derangere, Jean-David Fumet, Charlene Latour, Cedric Rebe, Pierre-Simon Bellaye, Coureche-Guillaume Kaderbhai, Aodrenn Spill, Bertrand Collin, Mary B. Callanan, Aurelie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Sylvain Ladoire, Bertrand Routy, Philippe Joubert, Francois Ghiringhelli
Summary: Chemotherapy combined with MEK inhibitor enhances the sensitivity of lung cancer cells to immune checkpoint inhibitors by inducing CXCL10 expression and CD8(+) T cell recruitment. The study also highlights the role of TLR9- and OPTN-dependent mitophagy in enhancing the efficacy of chemoimmunotherapy.
Article
Oncology
Aurelie Bertaut, Yann Touchefeu, Julie Blanc, Olivier Bouche, Eric Francois, Thierry Conroy, Pascal Artru, Antoine Adenis, Jessica Gobbo, Christophe Borg, Francois Ghiringhelli, Jaafar Bennouna
Summary: Survival after failure of first-line chemotherapy is short in mCRC. Consideration should be given to symptom palliation and therapy toxicity in treatment selection. Assessment in PRODIGE18 study shows no significant differences in patient's quality of life between two treatment arms.
CLINICAL COLORECTAL CANCER
(2022)
Article
Oncology
Morgane Stouvenot, Aurelia Meurisse, Angelique Saint, Bruno Buecher, Thierry Andre, Emmanuelle Samalin, Marine Jary, Farid El Hajbi, Nabil Baba-Hamed, Simon Pernot, Marie-Christine Kaminsky, Olivier Bouche, Jerome Desrame, Mustapha Zoubir, Denis Smith, Francois Ghiringhelli, Aurelie Parzy, Christelle de la Fouchardiere, Hamadi Almotlak, Angelique Vienot, Marion Jacquin, Julien Taieb, Thierry Nguyen, Dewi Vernerey, Christophe Borg, Stefano Kim
Summary: Second-line treatments are effective for patients with SCCA. Ablative treatment is the best option for patients with oligometastatic progression. If ablative treatment is not possible, systemic therapy using immunotherapy or chemotherapy can be recommended.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Jean marc Phelip, Jerome Desrame, Julien Edeline, Emilie Barbier, Eric Terrebonne, Pierre Michel, Herve Perrier, Laetitia Dahan, Vincent Bourgeois, Faiza Khemissa Akouz, Emilie Soularue, Valerie Lebrun Ly, Yann Molin, Thierry Lecomte, Francois Ghiringhelli, Romain Coriat, Samy Louafi, Cindy Neuzillet, Sylvain Manfredi, David Malka
Summary: This study compared triplet chemotherapy with doublet chemotherapy in advanced biliary tract cancer treatment, with the results showing triplet chemotherapy did not meet the primary study endpoint. Doublet chemotherapy remains the first-line standard in advanced BTC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Meriem Messaoudene, Reilly Pidgeon, Corentin Richard, Mayra Ponce, Khoudia Diop, Myriam Benlaifaoui, Alexis Nolin-Lapalme, Florent Cauchois, Julie Malo, Wiam Belkaid, Stephane Isnard, Yves Fradet, Lharbi Dridi, Dominique Velin, Paul Oster, Didier Raoult, Francois Ghiringhelli, Romain Boidot, Sandy Chevrier, David T. Kysela, Yves Brun, Emilia Liana Falcone, Genevieve Pilon, Florian Plaza Onate, Oscar Gitton-Quent, Emmanuelle Le Chatelier, Sylvere Durand, Guido Kroemer, Arielle Elkrief, Andre Marette, Bastien Castagner, Bertrand Routy
Summary: The study demonstrates that oral supplementation with polyphenol-rich berry camu-camu alters gut microbial composition in mice, leading to antitumor activity and enhanced anti-PD-1 response. The active compound castalagin enriches for specific bacteria and induces metabolic changes to support immunotherapy efficacy.
Article
Biochemistry & Molecular Biology
Julie Niogret, Valentin Derangere, Corentin Richard, Lisa Nuttin, Francois Ghiringhelli, Laure Favier, Leila Bengrine Lefevre, Anthony Bergeron, Laurent Arnould, Romain Boidot
Summary: Low-grade serous carcinoma is a less common subtype of serous carcinoma with better prognosis but poor response to chemotherapy. This study aims to evaluate the clinical benefit of MEK inhibitors in the management of advanced-stage low-grade serous carcinoma with KRAS or NRAS mutation. The results showed that MEK inhibitors, in combination with anti-EGFR antibody, provided disease stabilization in patients with RAS-mutated low-grade serous carcinoma. RB1 loss-of-function mutation may be a mechanism of resistance to MEK inhibitors in these patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Valerie Jooste, Leila Bengrine-Lefevre, Sylvain Manfredi, Valerie Quipourt, Pascale Grosclaude, Olivier Facy, Come Lepage, Francois Ghiringhelli, Anne-Marie Bouvier
Summary: Real-world data on the management and outcomes of pancreatic cancer showed that only half of elderly patients aged 75-84 with a surgically resectable tumor actually underwent resection, and a significant percentage of patients aged >= 85 refused chemotherapy, highlighting the need for expanded geriatric assessments.
Review
Oncology
Delphine Hudry, Solenn Le Guellec, Samuel Meignan, Stephanie Becourt, Camille Pasquesoone, Houssein El Hajj, Carlos Martinez-Gomez, Eric Leblanc, Fabrice Narducci, Sylvain Ladoire
Summary: The role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer (OC) patients is still not well understood. However, recent research suggests that understanding TILs in OC patients could be beneficial for immunotherapy.
Review
Oncology
Sylvain Ladoire, Cedric Rebe, Francois Ghiringhelli
Summary: Immune-checkpoint inhibitors have significantly impacted cancer management, but resistance remains a major issue. To overcome this, combination strategies with other therapies are being explored.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
David Bonnin, Sylvain Ladoire, Nathalie Briot, Aurelie Bertaut, Clement Drouet, Alexandre Cochet, Jean-Louis Alberini
Summary: This study aimed to assess the diagnostic performance of FDG-PET/CT scanning in women previously treated for invasive lobular carcinoma with suspected first recurrence and evaluate its impact on treatment changes and prognostic value. The results showed that FDG-PET/CT is an effective tool for detecting recurrence of invasive lobular carcinoma, although certain specific recurrence sites may impair its diagnostic performance.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Loick Galland, Nicolas Roussot, Isabelle Desmoulins, Didier Mayeur, Coureche Kaderbhai, Silvia Ilie, Audrey Hennequin, Manon Reda, Juliette Albuisson, Laurent Arnould, Romain Boidot, Caroline Truntzer, Francois Ghiringhelli, Sylvain Ladoire
Summary: Breast cancer is the most common cancer in the world, and advancements in technology allow for the identification of specific molecular alterations in tumor cells, leading to new treatment options. This review summarizes the clinical utility of genomic tests in evaluating homologous recombination repair deficiency for breast cancer treatment decisions.
Article
Oncology
Nesrine Mabrouk, Cindy Racoeur, Jingxuan Shan, Aurelie Massot, Silvia Ghione, Malorie Privat, Lucile Dondaine, Elise Ballot, Caroline Truntzer, Romain Boidot, Francois Hermetet, Valentin Derangere, Melanie Bruchard, Frederique Vegran, Lotfi Chouchane, Francois Ghiringhelli, Ali Bettaieb, Catherine Paul
Summary: Our study aimed to test the beneficial effect of the nitric oxide donor glyceryltrinitrate (GTN) in combination with the chemotherapy drug doxorubicin in the treatment of triple-negative breast cancer (TNBC). Using a mouse model of TNBC, we found that the combination of the two drugs induced greater tumor regression compared to monotherapies, which was correlated with stronger activation of the immune system and a decrease in immunosuppressive immune cells. These findings suggest a new therapeutic perspective for TNBC treatment.
Article
Imaging Science & Photographic Technology
Julien Odet, Julie Pellegrinelli, Olivier Varbedian, Caroline Truntzer, Marco Midulla, Francois Ghiringhelli, David Orry
Summary: This study aimed to identify risk factors for local recurrence (LR) after radiofrequency (RFA) and microwave (MWA) thermoablations (TA) of colorectal cancer liver metastases (CCLM). The size of the lesions and the nearby vessel were found to be significant risk factors for LR.
JOURNAL OF IMAGING
(2023)
